BIIB Jan 2025 175.000 call
| Previous close | 111.60 |
| Open | N/A |
| Bid | 120.00 |
| Ask | 128.00 |
| Strike | 175.00 |
| Expiry date | 2025-01-17 |
| Day's range | 111.60 - 111.60 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
- Simply Wall St.
Do Fundamentals Have Any Role To Play In Driving Biogen Inc.'s (NASDAQ:BIIB) Stock Up Recently?
Biogen's (NASDAQ:BIIB) stock is up by 3.0% over the past week. As most would know, long-term fundamentals have a strong...
- GlobeNewswire
Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals
TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that three additional detailed analyses from the Phase IIb clinical study (Study 201), evaluating the efficacy and safety of lecanemab for mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively know
- GlobeNewswire
Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting
TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai presented new analyses on amyloid-related imaging abnormalities (ARIA) with the use of antiplatelet and anticoagulant medications, isolated ARIA-H, and caregiver burden and health-related quality of life (QOL), from the re
